What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?

Konference: 2014 56th ASH Annual Meeting - účast ČR

Kategorie: Maligní lymfomy a leukémie

Téma: 902. Health Services and Outcomes Research – Malignant Diseases: New/Refined Prognostic Schemes/Pharmacoeconomics

Číslo abstraktu: 738

Autoři: Richard A. Larson; David V. Conti, Ph.D.; William V. Padula, PhD; Prof. Jane F. Apperley, MBChB, MD, FRCP, FRCPath; MD Michele Baccarani; MD Ekkehard Eigendorff; MD Francois Guilhot; Joelle Guilhot (Guillhot), PhD; M.D. Francois-Xavier Mahon, Ph.D.; Prof.MD Giovanni Martinelli; prof. MUDr. Jiří Mayer, CSc.; Martin Christian Mueller, MD; MD Dietger W Niederwieser; MD Susanne Saussele; MD Charles A. Schiffer; M.D. Richard T. Silver; MD Bengt Simonsson, PhD; Prof. Dr. Rüdiger Hehlmann

Datum přednesení příspěvku: 8. 12. 2014